Abstract:Background: Gastrointestinal immune-related adverse events are frequently caused by immune checkpoint inhibitors (ICIs) and often require interruption of cancer treatment. Compared with ICI colitis and enteritis, limited information exists about ICI gastritis. This study characterized clinical features and treatment outcomes of ICI gastritis. Methods: Consecutive cancer patients who received ICIs and underwent endoscopy with gastric biopsies while on ICIs from 2011 to 2021 were retrospectively assessed. Specific histopathologic features identified ICI gastritis. Results: Of 6450 ICI-treated patients, 162 (2.5%) underwent endoscopy with gastric biopsies. ICI gastritis was identified in 54 (33%) biopsied patients; 38 (70%) had concurrent ICI enteritis/colitis and 16 (30%) had isolated ICI gastritis. Dyspepsia (38%) and bloating (25%) were the most frequent symptoms of isolated ICI gastritis. Compared with patients with concomitant enteritis/colitis, patients with isolated gastritis were less likely to have diarrhea (13% vs 68%; p < .001) or abdominal pain (19% vs 47%; p = .07). Patients with isolated ICI gastritis less frequently required glucocorticoids (69% vs 92%; p = .04) and had lower incidence of ICI hold/withdrawal (13% vs 42%; p = .06). There was no association between severity or extent of luminal inflammation and antitumor response (p = .85 and p = .44, respectively). Endoscopically, gastric mucosa appeared normal in 11 (20%) patients with biopsy-proven ICI gastritis. Conclusion: ICI gastritis may present alone or more commonly with concurrent enteritis/colitis, which may differentiate its clinical course. Gastric biopsies are required to diagnose a substantial minority of endoscopically normal, clinically significant cases. Most patients with isolated gastritis can continue ICI therapy uninterrupted, but a notable proportion require glucocorticoids. Plain language summary: Immune checkpoint inhibitors are effective anticancer treatments, but can cause inflammatory toxicities, including of the stomach (gastritis), intestine, and colon. Limited information is available on gastritis triggered by these agents. Adult patients with cancer who were treated with immune checkpoint inhibitors and had an upper gastrointestinal endoscopy with biopsies of the stomach were examined. More than two-thirds (70%) of people with checkpoint inhibitor gastritis also had inflammatory changes of the small intestine and/or colon. Compared with patients with isolated checkpoint gastritis, the subgroup with concomitant enteritis/colitis more frequently had abdominal pain, diarrhea, needed steroids, and/or needed to pause or stop antitumor therapy.

Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis

Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course

Reconceptualization of immune checkpoint inhibitor-associated gastritis

A systematic review of gastritis as an immune-related adverse event in clinical interventions

Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review

Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis

Immune Checkpoint Inhibitor-Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease

S3946 Gut on Fire: Immune Checkpoint Inhibitor-Induced Gastrointestinal Inflammation

Immune checkpoint inhibitor-associated gastritis: Patterns and management

Mechanisms and biomarkers of immune-related adverse events in gastric cancer

Gastrointestinal toxicity of systemic oncology immunotherapy

Colitis due to cancer treatment with immune check-point inhibitors – review of literature and presentation of clinical cases

S5147 Steroid Refractory Immune Checkpoint Inhibitor Induced Severe Gastritis Responsive to Infliximab

Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors

Chronic gastrointestinal immune-related adverse events in patients exposed to immune checkpoint inhibitors

The development of persistent GI symptoms in melanoma patients who have had an immune checkpoint inhibitor-related GI toxicity

Gut microbiota shifts from onset to remission in immune checkpoint inhibitor-induced enterocolitis: a case report

Clinical Characteristics and Outcomes of Pembrolizumab Induced Gastritis: A Systematic Review of the Literature

[Pembrolizumab-induced gastritis with PDL1 histological expression]

Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer

Therapeutic Immunomodulation in Gastric Cancer